Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Lung cancer, Non small cell lung cancer (NSCLC)
Closed
Phase 3
This trial is comparing the combination of Dato-DXd, durvalumab and carboplatin with the combination of pembrolizumab and chemotherapy.
It is open to people with advanced non small cell lung cancer (NSCLC) who have not had treatment for their .
Recruitment start: 23 January 2023
Recruitment end: 15 August 2024
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Alastair Greystoke
AstraZeneca
Last reviewed: 14 August 2024
CRUK internal database number: 18622
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
